Regarding safety concerns, a serious event occurred in the context of HER2-targeting CAR therapy where the use of a HA CAR (based on the scFv 4D5, as employed in our study) led to a fatal outcome in a patient with colon cancer metastatic to the lungs and liver. The gene discussed is ERBB2; the disease is malignant colon neoplasm.